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1. Introduction  
Glioma is a type of invasive brain tumor, and the properties of the center region of the 
tumor differ from those of normal brain tissue. Accordingly, the macroscopic differences 
from normal brain tissue or differences in terms of properties such as hardness allow one to 
recognize that the glioma is, in fact, tumor tissue. The difference from normal brain tissue in 
the periphery of the tumor, i.e., the tumor’s region of infiltration, does not show glioma to 
be as evident, making it difficult to make any objective determination as to whether there is 
any tumor infiltration. The margin between the normal brain tissue and tumor tissue is not 
clearly discernible in the band of infiltration around the malignant brain tissue, often 
preventing the gross-total resection (GTR) of a malignant brain tumor. Researches have 
shown that GTR of a malignant brain tumor has a significant impact on patient survival 
(Filippini et al., 2006; Gorlia et al., 2006). Accordingly, any surgery on malignant glioma is 
performed for the purpose of GTR, and objectively determining the region of infiltration to 
perform GTR on malignant glioma is necessary to significantly affect patient survival. 
Photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) has enabled the 
objective assessment of tumor infiltration whenever surgery on glioma is to be performed 
(Stummer et al., 1998a, 1998b). When 5-ALA is administered, protoporphyrin IX (PpIX), 
which is a metabolite of 5-ALA, accumulates to a greater extent in the tumor cells than in 
normal brain cells. The PpIX used in the procedure reacts to light within the UV range, and 
emits a red fluorescent hue. Irradiation of tumor-infiltrated regions with UV-range light 
results in the regions appearing fluorescent red if tumor cells containing an accumulation of 
PpIX have infiltrated. This effectively allows for an objective assessment of tumor 
infiltration. Resection utilizing the fluorescence of the glioma after administration of 5-ALA 
has been shown to assist in the visualization of the tumor tissue during surgery. As a result, 
the use of 5-ALA is currently being praised as a new approach that allows for a significant 
increase in the potential to successfully perform GTR of malignant brain tumors (Stummer 
et al., 1998a, 1998b, 2006, 2011). 
This chapter will cover the principles of PDD using 5-ALA and provide commentary on the 
usefulness of this procedure for brain tumors. This will be followed by further commentary 
on the potential for PDD in regard to brain tumors, and finally a synopsis on the current 
limitations of and perspectives on this promising technique. 
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2. 5-ALA metabolic pathway  
2.1 5-ALA metabolism in normal cells 
5-ALA is a substance that naturally exists in the body. In the first stage, 5-Ala is produced 
via the condensation of glycine and succinyl-CoA by ALA synthetase (ALAS) in the 
mitochondria. This process receives negative feedback from heme, which is the end-
product. 5-ALA is actively transported via cytoplasm. In the next step, porphobilinogen 
(PBG) is created from ALA via ALA dehydratase. The actions of PBG deaminase (PBGD) 
and uroporphyrinogen III synthase compress 4 PBG molecules, effectively cyclizing a 
tetrapyrrole chain and producing uroporphyrinogen III. Uroporphyrinogen III is converted 
by uroporphyrinogen decarboxylase into coproporphyrinogen III, which is exposed to 
coproporphyrinogen oxidase in the mitochondrial intermembrane space. Decarboxylation 
and oxidation of the propionic side chains of the vinyl groups’ rings A and B ultimately 
form protoporphyrinogen IX in the cell nucleus. PpIX is synthesized from 
protoporphyrinogen IX via protoporphyrinogen oxidase activity, and heme is synthesized 
via the uptake of iron into the tetrapyrrole structure by ferrochelatase in the mitochondrial 
membrane (Fig. 1). Regarding mitochondrial ferrochelatase, all of the enzymes in the heme 
pathway that are dependent on mitochondrial energy generation display irreversibleactions 
and are partially adjusted via ALAS feedback control (Rimington & Riley, 1993). ALAS has 
the next lowest level of activity after PBGD, as the other enzymes display much high 
degrees of activity. When administered, 5-ALA is incorporated into cells. PBGD   
 
 
Fig. 1. Simplified metabolic pathway of 5-ALA-induced heme in cells 
www.intechopen.com
 Intraoperative Photodynamic Diagnosis of Brain Tumors Using 5-Aminolevulinic Acid 
 
229 
however, is rate-limiting, and the reactions do not proceed any further. Excessive 5-ALA is 
not metabolized and ALAS feedback control occurs, effectively controlling even the 
synthesis of 5-ALA in the cell. The resulting physiological state does not allow for synthesis 
of significant volumes of porphyrin or heme. External administration of a large volume of 5-
ALA, however, prevents feedback control from having any additional effect and results in 
generation of more porphyrin than normal. The level of activity is lowest after that of PBGD, 
however, so extremely excessive generation of porphyrin does not occur (Mustajoki P et al., 
1992). 
2.2 5-ALA metabolism in tumor cells 
5-ALA synthesis is the same in tumor cells as in normal cells, however, differences in 
enzyme activity, have been cited. In tumor cells, PBGD is not rate-controlling and 
metabolism is increased, so more heme is synthesized than in normal cells. Moreover, tumor 
cells show a relatively decreased level of ferrochelatase activity (Kaneko, 2008). Accordingly, 
administration of a large volume of extrinsic 5-ALA results in the 5-ALA being incorporated 
into tumor cells, progression of metabolism beyond PBG, and more porphyrin being 
produced than in normal cells (Utsuki et al., 2009).  
It has been reported that in patients whose normal brain cells do not display PpIX 
fluorescence, glioblastoma tissue, which displays intense PpIX fluorescence, shows an 
increase in all porphyrins from 5-ALA to PpIX (Kaneko, 2008). However, ferrochelatase is 
rate-limiting, so the PpIX is not converted to heme and excessively accumulates in the tumor 
cells. Actually, the only enzyme activity from 5-ALA to PpIX that has a negative correlation 
with PpIX is the ferrochelatase activity (Kaneko, 2008). These processes show that abnormal 
growth of malignant glioma cells causes increased cellular uptake of 5-ALA, resulting in an 
increase in heme intermediate metabolites containing PpIX and a decrease in heme-
synthesizing enzymes; particularly enzymes such as ferrochelatase. Accordingly, 
administration of 5-ALA results in increased concentration and accumulation of PpIX in 
tumor cells, making it an effective substance for photosensitivity (El-Sharabasy et al., 1992). 
The details concerning why ferrochelatase activity is relatively low in tumor cells are 
unknown. Downregulation of ferrochelatase mRNA expression has been identified in tumor 
tissue (Teng et al., 2011). Moreover, it is also known that generation of nitric oxide in tumor 
cells reduces ferrochelatase in the mitochondria and increases PpIX accumulation 
(Yamamoto et al., 2007). These processes likely represent the cause for the relatively low 
ferrochelatase activity in tumor cells. 
3. PDD using 5-ALA 
PDD using 5-ALA was used by the authors at Kitasato University Hospital on 204 patients 
with brain tumor or suspected of brain tumor. 5-ALA was administered after approval by 
the IRB. Approval was obtained to administer 5-ALA to all patients prior to surgery. It was 
administered in 78 cases with glioblastoma (including 22 relapse cases), 25 cases with 
glioma grade III (including 6 relapse cases), 18 cases with glioma grade II (10 astrocytomas, 
8 oligodendrogliomas), 2 cases with pilocytic astrocytoma, 2 cases with ependymoma, 2 
cases with subependymal giant cell astrocytoma (SEGA), 1 case with choroid plexus 
papilloma, 1 case with atypical teratoid/rhabdoid tumor (AT/RT), 1 case with central 
neurocytoma, 9 cases with hemangioblastoma, 6 cases with germinoma, 20 cases with 
malignant lymphoma, 6 cases with pituitary adenoma, 10 cases with meningioma, 4 cases 
with neurilemmoma, 15 cases with metastatic brain tumor, and 4 cases with pseudotumor. 
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3.1 Administration of the 5-ALA 
When 5-ALA is orally administered, PpIX begins to accumulate at the lesion 1 hour later. 
The accumulation peaks 4 to 6 hours after administration, declining afterwards. To enable 
accumulation of PpIX within the tumor to a peak level 1 hour after anesthesia and coincide 
with initiation of tumor excision, each patient was orally administered 1 g of 5-ALA (5-ALA 
hydrochloride, Cosmo Bio Co., Let., Tokyo, Japan) that was dissolved in 20 ml of 5% glucose 
solution 2 hours prior to initiation of the anesthesia. Regarding steroid administration, 
betamethasone (8-16 mg) was administered 1 hour prior to initiation of the anesthesia only 
in cases of severe cerebral edema. 
3.2 Excitation light and fluorescent observation 
PpIX reacts to UV light by displaying a red fluorescent hue. To explain, irradiation of the 
PpIX with excitation light results in absorption of light energy and a change from a ground 
state to a singlet excited state. Then, fluorescence is emitted when there is the shift from the 
singlet excited state to the ground state. The more PpIX in a tissue and the more intense the 
excitation light, the stronger the display of fluorescence by PpIX. Among the wavelengths 
that excite PpIX are 410 nm, 510 nm, 545 nm, 580 nm, and 630 nm. PpIX is most intensely 
excited by light around of ~405 nm. We used a semiconductor laser device (VLD-V1 version 
2 M & M Co., Ltd., Tokyo, Japan) to provide the excitation light. This device was used to 
irradiate the tumor tissue via optical fiber as close to the tumor as possible with excitation 
light at a wavelength of 405 nm and an output of 120 mW (Fig. 2). This was observed using a 
cut-off filter that blocks the transmission of light at a wavelength < 430 nm and is attached 
to a microscope. The wavelengths included in the microscope’s irradiation light near 400 nm 
are blocked, which lowers the PpIX photobleaching effect of the irradiation light. It blocks 
the excitation light, allowing for easier observation of PpIX fluorescence. 
A neurosurgical microscope for fluorescence incorporated into a microscope system was 
developed to irradiate with excitation light, and was the principal instrument used. The 
device could switch from conventional white light to violet-blue excitation light and was 
very convenient to use (Stummer et al., 1998a). This system also provided a favorable 
contrast because, after image processing, it displayed fluorescence which was detected via a 
CCD camera. 
One advantage of these methods compared to the laser method is that they allow for 
detection of fluorescence over the entire area observed by the microscope. When irradiating 
excitation light with a laser, the scope of irradiation is narrow and allows for detection of 
fluorescence only within the narrow area observed by the microscope (Haj-Hosseini et al., 
2010; Utsuki et al, 2006). Laser methods, however, do have benefits over systems 
incorporated into microscopes. The biggest advantage is that use of this technology 
allowsfor excitation of fluorescence even with a low PpIX level. When excitation light is 
irradiated from a microscope, the distance to the target tumor tissue increases, effectively 
weakening the power of the excitation light that reaches the tumor tissue and resulting in 
weaker fluorescence. When optical fibers are used to irradiate with laser, the optical fiber is 
brought to a spot very near the tumor tissue, and this allows for irradiation of excitation 
light on the target tissue with a strong output. Also, even if this results in a low level of PpIX 
accumulation, the irradiation by strong excitation light allows for detection of fluorescence 
with a low level of PpIX. 
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3.3 Fluorescent analysis 
PpIX reacts to light in the UV field, emitting fluorescence at two bimodal peaks, i.e., 636 nm 
and 704 nm. We perceive blood to be red, and may not be able to differentiate blood from 
the red coloring of PpIX. We usually perceive wavelengths between 610 and 750 nm to be 
red. Oxyhemoglobin has an absorption spectum of 400 - 630 nm. This differs from that of 
PpIX, so they can be differentiated via wavelength analysis. Moreover, if the PpIX level is 
low, the fluorescence can be confirmed macroscopically. Also, wavelength analysis allows 
for detection of minute levels of PpIX fluorescence that cannot be observed macroscopically. 
We used a spectrometer and accessory software (BW-Spec V3.09; B & W TEK, Inc., Newark, 
Del., U.S.A.) to analyze the spectrum waveform via PC (Fig. 2). Wavelength analysis when 
performing PDD is necessary to make objective determinations regarding PpIX fluorescence 





Fig. 2. Photo of intraoperative brain tumor fluorescence using a semiconductor laser device. 
The tumor emits red fluorescence upon exposure to a laser light with peak wavelength of 
405 nm and a light output of 120 mW through optical fiber. Tumor emissions were analyzed 
by personal computer via spectrometer through a second optical fiber in parallel. PpIX-
specific fluorescence and relative intensity were measured. The surgeons made observations 
via cut-off filter, so were unable to see the irradiated 405 nm blue light (blue arrows), yet the 
red hue of the PpIX was enhanced (red arrows). 
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3.4 Results of PDD for brain tumors 
The strength of the perceived PpIX fluorescence is correlated with the relative strength 
measured with a spectrometer. When strong PpIX fluorescence is perceived, a bimodal 
spectrum for PpIX can be observed and the height of the 636 nm peak is at least 3,000. Weak 
PpIX fluorescence was observed at a height of 636 nm (the peak) between strengths of 3,000 
and 1,000. Strong PpIX fluorescence was observed in 76 cases with glioblastoma (including 
all recurrent cases), 15 cases with glioma grade III (including all recurrent cases), 5 cases 
with glioma grade II (1 astrocytoma, 4 oligodendrogliomas), 2 cases with pilocytic 
astrocytoma, 2 cases with ependymoma, 1 case with SEGA, 1 case with choroid plexus 
papilloma, 1 case with AT/RT, 1 case with central neurocytoma, 9 cases with 
hemangioblastoma, 5 cases with germinoma, 12 cases with malignant lymphoma, 8 cases 
with meningioma, and 1 case with pseudotumor. Moreover, weak PpIX fluorescence was 
observed in 4 cases with glioma grade III, 6 cases with glioma grade II (3 astrocytomas, 3 
oligodendrogliomas), 1 case with SEGA, 1 case with germinoma, 4 cases with malignant 
lymphoma, 1 case with meningioma, 11 cases with metastatic brain tumor, and 3 cases with 
pseudotumor. A clear enhancing effect of the entire/part of the tumor was observed in the 
magnetic resonance images (MRIs) in all of these cases except 4 cases with glioma grade II (3 
astrocytomas, 1 oligodendroglioma). 
PpIX fluorescence could not be macroscopically observed in 2 cases with glioblastoma, 6 
cases with glioma grade III, 7 cases with glioma grade II (6 astrocytomas, 1 
oligodendroglioma), 4 cases with malignant lymphoma, 6 cases with pituitary adenoma, 1 
case with meningioma, 4 cases with neurilemmoma, or 4 cases with metastatic brain tumor. 
PpIX fluorescence was not observed even if there was a clear enhancing effect on the MRI in 
2/74 cases with glioblastoma (not including 2 cases in which there was not an enhancing 
effect), 3/22 cases with glioma grade III (not including 3 cases in which there was not an 
enhancing effect), 4/18 cases with malignant lymphoma (not including 2 cases in which 
there was not an enhancing effect), 6/6 cases with pituitary adenoma, 1/6 cases with 
meningioma, 4/4 cases with neurilemmoma, and 4/15 cases with metastatic brain tumor. 
This said, among the cases in which the above mentioned PpIX fluorescence could not be 
macroscopically confirmed, it was possible to detect fluorescence of PpIX with a 636 nm 
peak using a spectrometer in 4 cases with glioma grade II (3 astrocytomas, 1 
oligodendroglioma), 3 cases with malignant lymphoma, 1 case with meningioma, and 1 case 
with metastatic brain tumor. 
These findings show that there may be some tumors (even benign tumors) that allow for 
PPD using 5-ALA in cases in which there is an enhancing effect on the MRI, but it may be 
difficult to use PDD with 5-ALA for pituitary adenoma or neurilemmoma, even if the MRI 
shows an enhancing effect. 
4. The role of PDD in brain tumors 
4.1 Tumor confirmation: Assisting tumor resection of invasive tumors 
Glioma surgery probably receives the most benefits from PDD using 5-ALA. Even if the 
central region of a tumor in a malignant glioma case clearly displays different properties 
from normal brain cells, the peripheral region cannot be differentiated (normal brain from 
tumor). Also, even if there is an enhancing effect on MRI in that region, it can be difficult to 
determine whether there is tumor infiltration during surgery. A randomized controlled 
multicenter phase III trial on malignant gliomas showed a significantly higher percentage of 
GTR (gross-total resection) of the regions for which there was an enhancing effect on MRI 
among those who underwent surgery after PDD using 5-ALA, vs. those for whom 5-ALA 
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was not used (Stummer et al., 2006). Accordingly, the 6-month progression-free survival 
(PFS) in the group in which 5-ALA was used was 46% as opposed to 28% in the control 
group, i.e., PFS in the group in which 5-ALA was used was significantly longer (Stummer et 
al., 2011). Moreover, the group in which 5-ALA was used showed lower cumulative 
reoperation rates. PDD using 5-ALA is very helpful in glioma surgery in order to determine 
tumor infiltration and for an objective determination on where (what region) to resect. 
In the same patients, PpIX fluorescence and tumor cell density are roughly proportionate to 
each other. We will show you one example of our experience. In a case of anaplastic 
oligodendroglioma, tumor cells with heteromorphic nuclei proliferated in a sheet-like 
manner in the tumor’s central region (Fig. 3 B). The distinct red fluorescence of PpIX  was 
observed in this region (Fig. 3 A,in circle) and a PpIX spectrum with a relatively high peak 
of 636 nm was displayed (Fig. 3 A). The Ki-67 staining index (SI) for this region was 14% 
(Fig. 3 C). In the tumor’s region of infiltration (Fig. 4 B), weak red fluorescence of the PpIX 
(Fig. 4 A, in  circle) and a PpIX spectrum with a low peak at 636 nm were observed (Fig. 4 
A). The Ki-67 SI of this region was 3% (Fig. 4 C). Moreover, in the peripheral region, 
infiltration of a very small number of tumor cells with heteromorphic nuclei on an edema-
like background was observed (Figure 5 C) yet PpIX red fluorescence was not observed 
(Figure 5 B). However, a PpIX spectrum with a very low peak was observed at 636 nm 
(Figure 5 A). In this region, the PpIX fluorescence could not be confirmed macroscopically, 






             A    B   C 
 
Fig. 3. Image of tissue from the central region of a tumor, the PpIX fluorescence for the 
region, and the fluorescence analysis results via spectrometer. It shows a proliferation of 
heteromorphic tumor cells with a halo around the nucleus (B, HE staining, original 
magnification X200). Irradiation of this region with laser showed a strong PpIX fluorescence 
(A, in circle). This spectrum of fluorescence featured a peak at 636 nm, indicating PpIX 
fluorescence (A). The relative intensity of this peak was 14000. At 14%, the Ki-67 staining 
index (SI) of this region was relatively high (C, Ki-67 staining, original magnification X200). 
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Fig. 4. Image of tissue from the region of infiltration into the brain around the tumor, the 
PpIX fluorescence for the region, and the fluorescence analysis results via spectrometer. 
Normal brain cells can be seen between the infiltrating tumor cells, so the tumor density is 
lower than in Fig. 3 (B, HE staining, original magnification X200). Weak PpIX fluorescence 
was observed (A, in circle) after irradiation of the region with a laser. The fluorescence 
spectrum peaks at 636 nm, with the relative intensity of the peak at 2500 (A). The Ki-67 
staining index (SI) of this region was 3% (C, Ki-67 staining, original magnification X200). 
 
 
           A    B   C 
 
Fig. 5. Image of tissue featuring more of the peripheral region than in Fig. 3, the PpIX 
fluorescence for the region, and the fluorescence analysis results via spectrometer. A small 
number of tumor cells with heteromorphic nuclei have infiltrated edema-like brain cells, 
and disperse reactive astrocyte can also be seen (C, HE staining, original magnification 
X200). Irradiation of this region with laser did not allow for observation of the red 
fluorescence of PpIX (B). This fluorescence spectrum peaks at 636 nm, with fluorescence of a 
slight level of PpIX likely detected. The relative intensity of the peak was 500 (A). 
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Glioma surgery in eloquent areas is conducted using sensory-evoked potential (SEP), motor-
evoked potential (MEP), awake surgery, and other methods. Cortical and subcortical 
stimulation must be conducted to identify the cortical pathway of the functional field/lesion 
periphery and determine the scope of resection. For example, if the permanent decrease in 
MEP amplitude obtained via transcranial electronic stimulation is at least 50% compared to 
baseline, tumor resection should be removed as an optio. (Feigl et al., 2010). This is because 
once this occurs; continuing with excision of the tumor significantly increases the percentage 
of post-surgical neuropathy and lowers patients’ quality of life (QOL). However, there are 
limitations to the scope of identification for these monitoring. In particular, if tumor 
resection is the primary measure in a case where the eloquent areas and tumor body are 
proximal, it facilitates worsening of patient QOL, and excessive concern about post-surgical 
dysfunction can result in much of the tumor remaining after surgery. In such a case, if the 
strength of the PpIX fluorescence, even in the regions considered to have function differs, 
more detailed examination of the scope of the function of the region can enable additional 
resection of the region(s) with strong PpIX fluorescence (region with significant tumor 
infiltration) and increase the glioma excision rate. 
4.2 Identification of tumor’s malignant regions: Determination of glioma grading 
Tissue heterogeneity is normal in diffuse infiltrating glioma (Coons et al., 1993; Paulus & 
Peiffer, 1989). One of the reasons is that genetic mutation occurs in a portion of the tumor, 
and this is also one reason for it becoming malignant. To accurately ascertain how malignant 
a tumor is, the region that has become malignant must be left as a specimen. Moreover, 
whether a tumor has become malignant in that region or not has an impact on the decision 
regarding the scope of surgical excision if the tumor is in the vicinity of eloquent areas. 
Contrast-enhanced MRI and image diagnostics such as positron emission tomography (PET) 
using an amino acid (e.g., methionine or 18F-F-fluoroethyl-L: -tyrosine) tracer represent 
examples of pre-surgical image diagnostics that can be used to determine the malignant 
regions of the tumor. Contrast-enhanced MRI often does not show an image of WHO grade 
II glioma, but it does display a ''patchy and faint'' enhancing effect and the tumor’s most 
active cells may exist in this region (Pallud et al, 2009). In PET diagnosis, the region with the 
highest accumulation of tracer represents the region in which the tumor cell metabolism 
activity is highest (Goldman et al., 1997; Sadeghi et al., 2007). It is difficult to identify these 
regions during surgery. This is because even if a navigation system is used, craniotomy, 
brain shift due to CSF loss/gravity, as well as cerebral edema can result in targeted 
deviation. PDD using 5-ALA is useful for determining this factor (Widhalm et al., 2010). 
Fluorescence is observed in WHO grade III glioma regions with high cell mitotic activity, 
but less so in regions tantamount to WHO grade II glioma with low cell mitotic activity 
(Ishihara et al, 2007). It has been reported that the higher the grade of glioma, the higher the 
PpIX concentration tends to be in tissue (Kaneko , 2008; Johansson et al., 2010). The post-
surgical treatment regimen changes according to whether or not the WHO grade III glioma 
region remains as a specimen. Those patients are initiated on radiation therapy and 
chemotherapy immediately after surgery if diagnosed with WHO grade III glioma. 
However, if those patients are diagnosed with WHO grade II glioma, watchful waiting 
without any treatment may be a temporary option (Mittal et al., 2008; van den Bent et al., 
2005). This is because even if irradiation is used immediately after surgery, it has been 
shown that there is no significant difference in total survival if it is used when the patient’s 
post-surgical status has worsened (van den Bent et al., 2005). Considering that use of 
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irradiation immediately after surgery results in a significantly longer PFS, , when a cell 
group with high mitotic activity in a very small portion of the tumor is likely turning 
malignant, it is possible that worsening of progressive neurological deficit may immediately 
be observed. Accordingly, such a case  legitimizes use of irradiation immediately after 
surgery. In this way, PDD using 5-ALA is useful for determining detailed treatment 
regimens for WHO grade II to III glioma. 
4.3 Confirmation of tumor resection region: Confirmation of validity of biopsy region 
If the targeted lesion is small when conducting a biopsy, a minute error can prevent accurate 
diagnosis. This makes it necessary to confirm whether the target region is being excised. CT 
or MRI during or after surgery can be used to confirm whether the targeted region has been 
removed, but this requires time and effort. In such a case, PDD with 5-ALA can be used on a 
real-time basis to confirm whether the targeted region has been excised. If PpIX fluorescence 
can be detected from the excised tissue sample, it allows for confirmation that the targeted 
lesion area has been excised.  
Here, we will present an actual example of this. We used the Leksell Stereotactic System 
(Elekta, Stockholm, Sweden) under MRI-guidance to conduct biopsy, and used a side cut 
biopsy needle kit (Elekta, Stockholm, Sweden) as biopsy forceps. This forceps can excise 
specimens up to 1.4 mm in diameter and 10 mm of length. Prior to surgery, this was a 
suspected case of malignant lymphoma. We planned to obtain a biopsy of a 7mm lesion in 
the right-frontal lobe (Fig. 6 A). Irradiation of the tissue excised with forceps using a 405 nm 
laser allowed for observation of the red PpIX fluorescence in a portion of the tissue (Fig. 6 
B). Tumor cell infiltration can be seen in the region of the tissue sample in which PpIX 
fluorescence was observed (Fig. 6 C). Moreover, the regions in which no PpIX fluorescence 
was observed did not show any tumor cell infiltration. Naturally, not all lesions allow for 
observation of PpIX fluorescence, so this method is not effective in lesions in which there is 
no PpIX accumulation. In such a case, image diagnostics after biopsy becomes necessary. 
 
 
A   B   C 
Fig. 6. Image shows a gadolinium-enhanced axial MRI image (A). A 7 mm lesion with a 
uniform enhancing effect can be seen proximal to the anterior horn of the lateral ventricle in 
the right frontal lobe. Irradiation with a 405 nm laser on the excised tissue showed the red 
fluorescence of PpIX over half of the tissue (arrow), but no fluorescence on the remaining of 
half (arrowhead) (B). The tissue image shows a clear distinction between the region 
infiltrated with tumor cells (arrow) and those not infiltrated (arrowhead) (C, HE staining, 
original magnification X40). In these regions, the portion showing PpIX fluorescence and 
that showing the tumor’s region of infiltration concurred. 
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4.4 Significance of PDD using 5-ALA for benign tumor: Confirmation of remaining 
tumor 
Recurrence is possible in benign brain tumors whereby the boundary with the periphery 
brain tissue is clear-cut. As is the case of meningioma, there are times in which GTR cannot 
be conducted in order to maintain the blood vessels/nerves in the region and within the 
tumor. However, there are cases of recurrence even after a surgeon has conducted GTR. The 
biggest reason for recurrence/relapse in such tumors is tumor remaining after excision. 
PDD using 5-ALA can be utilized to check for any remaining tumor after GTR procedures 
(Shimizu et al., 2006; Utsuki et al., 2008). PDD using 5-ALA can be used in most cases of 
meningioma, hemangioblastoma, and pilocytic astrocytoma, etc., because it serves as a 
useful detection method in such types of tumors (Coluccia et al., 2010). 
Tumors in meningioma cases are mostly benign with a clear-cut boundary between the 
tumor and the brain, but there can be subpial infiltration even if WHO grade I, and this is 
quite common in recurrent cases. There are also some cases in which these tumors infiltrate  
bone and dura mater, creating difficulties in the resected region. if tumor infiltration into the 
skull base is detected, there are times in which the tumor will be left, because it cannot be 
adequately detached. In such cases, PDD using 5-ALA can be useful in meningioma in order 
to diagnose the tumor infiltration region (Kajimoto et al., 2007). In meningioma cases, dural 
tail sign can be observed in regions in which tumor is attached. These regions can show 
tumor infiltration, but also dilated blood vessels and inflammation (Rokni-Yazdi et al., 
2009). Here, we have used PDD with 5-ALA to determine whether the meningioma has 
infiltrated the dura mater. If it has, PpIX fluorescence can be observed (Fig. 7 A). Tumor 
infiltration into this region can also be confirmed histologically (Fig. 7 B). 
 
 
  A     B    
Fig. 7. Image shows PDD during surgery on region of infiltration in a dura mater in a case of 
meningioma. In the tumor’s region of infiltration into the dura mater, the PpIX in the tumor 
reacted to the laser, allowing for observation of fluorescence (A). The tissue sample from 
this region shows a tumor mass inside a thin layer of dura mater, indicating that the tumor 
has infiltrated the dura mater (B, HE staining, original magnification X40). 
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Hemangioblastoma is a type of cancer featuring benign tumors with frequent recurrence 
even after GTR. A part of recurrent hemangioblastoma cases include to occur by a genetic 
problem. Some recurrent cases in regard to the tumor can be due to the inability to resect 
tumor cells that have infiltrated brain parenchyma or a cyst wall accompanying the tumor 
(Bishop et al., 2008). Also, PDD using 5-ALA can be useful in diagnosing residual tumor, 
even when it is difficult to ascertain (Utsuki et al., 2010). 
5. Precautions in regard to PDD using 5-ALA 
5.1 Photobleaching effect 
There is great variance in tumor excision rates among surgeons even when using PDD with 
5-ALA, the same device, or the same reagents. This is largely because this technique 
depends on the skill level of the surgeon. While tumors can be visualized on an objective 
basis, there likely are many aspects that depend on a surgeon’s knowledge and experience 
when it comes to the detailed regions. Also, one factor involves the characteristics of the 
device being used. Another is the PpIX photobleaching effect due to the relative light 
exposure (Stummer et al., 1998b). Light-sensitive substances such as PpIX absorb light 
energy when exposed to light for a certain period of time, causing a change from a ground 
state to a singlet excited state. PDD has been used so that light-sensitive substances in a 
singlet excited state emit a fluorescent hue and shift to a ground state. This process does not 
always occur however, e.g., a substance in a singlet excited state can be transformed into a 
triplet excited state, generating free radicals, radical ions, and singlet oxygen, and effectively 
damaging the periphery cells. Photodynamic therapy (PDT) has used this. In this situation, 
PpIX (the light-sensitive substance) is not visible. The lower the level of PpIX, the earlier 
photobleaching occurs, although, this tends not to occur very often in the central region of 
the tumor where the PpIX level is high. In a tumor’s region of infiltration, the fluorescence 
of the PpIX fades before anybody notices due to the low PpIX level (Utsuki et al., 2007a). 
Light in the UV field does not reach deep areas, so there may be PpIX remaining in the 
tissue directly below the region in which photobleaching has occurred. To avoid 
overlooking fluorescence because of photobleaching, and particularly in the region of 
infiltration of an invasive tumor, when checking for residual tumor, it is necessary to 
remove a small amount of surface tissue to check for any PpIX fluorescence in the newly 
appearing tissue. 
5.2 Pseudonegative fluorescence 
Stummer et al have reported some cases of malignant glioma not showing PpIX fluorescence 
even after showing a gadolinium-enhancing effect in an MRI (Stummer et al., 1998b). The 
blood brain barrier (BBB) is one of the problems. Deterioration of the BBB is an important 
factor required to allow 5-ALA to reach tumor cells. If there is a tumor around which the 
BBB has not deteriorated, 5-ALA tends not to reach the tumor cells, preventing successful 
use of PDD (Miyatake et al., 2007). Moreover, steroids are often used on edema 
accompanying brain tumor. A tightening effect caused by the steroids makes it difficult for 
5-ALA to leak from deteriorated BBB around the tumor, possibly resulting in a lower supply 
of 5-ALA to the tumor cells (Grabb & Gilbert , 1995). The extent of steroid use that impacts 
the BBB permeability to 5-ALA has yet to be identified. Dexamethasone (12 mg /daily) does 
not appear to impact 5-ALA permeability (Stummer et al., 2006). This said, there are some 
cases in which the tumor does not show PpIX fluorescence after 5-ALA, even in non-brain 
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tumors (Hoda & Popken, 2009). This indicates that the BBB is not the only reason for failure 
of PDD using 5-ALA. Another cause may be in the tumor, but it must be noted that there are 
some cases in which PpIX fluorescence is not observed in tumors that normally should 
allow for PDD. 
Moreover, the excitation light used when conducting PDD is light in the UV field, so PDD 
can usually only be used for the surface tissue. If necrotic tissue is on the surface, or a tumor 
is in a brain ventricle covered by brain ventricle ependyma, etc., there are cases in which 
tumor PpIX cannot be detected. If so, this tissue should be removed to conduct PPD. 
5.3 Psudopositive fluorescence 
PpIX fluorescence is observed in some cases even if a brain tumor is not present. Based on 
our experience, PpIX fluorescence is observed even when there are no tumor cells, for 
example, in cases with brain abscess, multiple sclerosis, or remarkable infiltration of reactive 
astrocytes and macrophages in relapsed tumors (Miyatake et al., 2007; Utsuki et al., 2007b). 
PpIX fluorescence is observed even in cases of radiation necrosis without tumor recurrence 
(Miyatake et al., 2007) or a metastatic brain tumor’s edema field (Utsuki et al., 2007a). For 
whatever reason, PpIX fluorescence is observed even outside the brain in cases of strong 
inflammatory cell infiltration (Filbeck et al.; 1999). A gadolinium-enhancing effect on MRI 
often occurs in regions of inflammatory cell infiltration. There are also positive findings in 
regards to PET using L-[methyl-11C] methionine, which tends not accumulate in non-
neoplastic brain lesions or be impacted by local inflammatory reaction, and the metabolism 
increases due to the inflammatory cells (Kawai et al., 2010). In such regions, heme synthesis 
is very common, as is the production of PpIX, which likely results in fluorescence being 
observed with PDD. Moreover, the PpIX produced by the tumor leaks to the periphery, 
resulting in PpIX being observed in the tumor’s peripheral region, even if there is not tumor 
infiltration (Utsuki et al., 2007a). When employing PDD using 5-ALA, it is necessary to 
conduct surgery with the knowledge that tumor cells may not be present even if PpIX 
fluorescence is observed. 
5.4 Toxicity and side effects of 5-ALA 
5-ALA is an endogenous substance synthesized in the body, and is very safe. The only type 
of patients absolutely contraindicated for 5-ALA is porphyria patients. The most common 
side effect of oral administration of 5-ALA is temporary hepatic dysfunction (25%), with the 
incidence of nausea/vomiting being slightly lower. It causes virtually no other side effects, 
and there are no serious side effects as long as the oral dose of 5-ALA does not exceed 60 
mg/kg and IV dose, 30 mg/kg (Mustajoki et al., 1992; Webber et al., 1997a). Erythema, 
edema, hyperpigmentation, etc occur in rare occasions, and require respective attention 
(Steinbauer et al., 2009). Excessively administered 5-ALA is completely excreted from the 
kidneys in 24 hours, but slower if the patient suffers from renal dysfunction (Webber et al., 
1997b). Some 5-ALA is metabolized in the liver. If a patient suffers from renal dysfunction or 
hepatic dysfunction, the potential for phototoxocity may rise unless the dose of 5-ALA is 
either reduced or administration is discontinued. 
Past research has shown that administration of ALA once or several times results in a high 
concentration of serum porphyrin among cancer patients or healthy volunteers, but no 
symptoms of porphyria (Mustajoki et al., 1992; Utsuki et al., 2009). Moreover, the porphyrin 
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level was observed to be higher than the level that causes attacks among porphyria patients. 
Accordingly, even if administration of 5-ALA causes a high concentration of porphyrin, it 
will not result in symptoms often observed in cases of porphyria. 
6. Conclusions and future directions 
Utilization of PDD with 5-ALA in cases of invasive brain tumor increases the rate of GTR 
and promises improved prognosis. It allows for confirmation of residual tumor even in 
cases with a benign tumor, so PDD may be helpful in the reduction of recurrence. The extent 
of fluorescence in PDD differs according to the level of PpIX and the strength of excitation 
light. Moreover, measurement of the spectrum of fluorescence allows for detection of PpIX 
fluorescence that cannot be observed macroscopically. When performing PDD using 5-ALA, 
the surgeon must know to perform surgery, about the possibility of the photobleaching 
effect, pseudopositive, and pseudonegative, etc.  
Further studies should focus on identifying tumors in which PpIX does not accumulate and 
the mechanism as well as the development of methods to enhance PpIX accumulation in 
benign glioma in which PpIX does not tend to accumulate. Moreover, a certain degree of 
success has been achieved from in vitro experiments on PDT using PpIX, so there is 
anticipation that it can be used as a part of therapy on tumors that are difficult to excise.  
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